- Home
- KLAC vs CVKD Comparison
KLAC vs CVKD Comparison
Compare KLAC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLAC
- CVKD
- Stock Information
- Founded
- KLAC 1975
- CVKD 2022
- Country
- KLAC United States
- CVKD United States
- Employees
- KLAC N/A
- CVKD 4
- Industry
- KLAC Electronic Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- KLAC Technology
- CVKD Health Care
- Exchange
- KLAC Nasdaq
- CVKD Nasdaq
- Market Cap
- KLAC N/A
- CVKD 31.5M
- IPO Year
- KLAC N/A
- CVKD 2023
- Fundamental
- Price
- KLAC $580.11
- CVKD $15.50
- Analyst Decision
- KLAC Buy
- CVKD Strong Buy
- Analyst Count
- KLAC 20
- CVKD 1
- Target Price
- KLAC $832.60
- CVKD $32.00
- AVG Volume (30 Days)
- KLAC 951.5K
- CVKD 30.6K
- Earning Date
- KLAC 04-24-2025
- CVKD 03-13-2025
- Dividend Yield
- KLAC 1.09%
- CVKD N/A
- EPS Growth
- KLAC 20.61
- CVKD N/A
- EPS
- KLAC 23.75
- CVKD N/A
- Revenue
- KLAC $10,846,957,000.00
- CVKD N/A
- Revenue This Year
- KLAC $23.97
- CVKD N/A
- Revenue Next Year
- KLAC $3.84
- CVKD N/A
- P/E Ratio
- KLAC $26.14
- CVKD N/A
- Revenue Growth
- KLAC 12.15
- CVKD N/A
- 52 Week Low
- KLAC $609.40
- CVKD $5.40
- 52 Week High
- KLAC $896.32
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- KLAC 26.32
- CVKD 35.74
- Support Level
- KLAC $655.42
- CVKD $16.15
- Resistance Level
- KLAC $695.62
- CVKD $19.03
- Average True Range (ATR)
- KLAC 21.08
- CVKD 1.21
- MACD
- KLAC -10.37
- CVKD -0.28
- Stochastic Oscillator
- KLAC 3.74
- CVKD 3.99
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.